Rating Change
Oppenheimer reiterated its Outperform rating on Humana Inc. (NYSE:HUM) on October 09, 2026.
Oppenheimer reiterated its Outperform rating on Humana Inc. (NYSE:HUM) on October 09, 2026.

At publication ·
Humana Inc. (NYSE:HUM) · reiterate
At a glance
Oppenheimer reiterated its Outperform rating on Humana Inc. (NYSE:HUM) on October 09, 2026.
Humana Inc. operates in the Healthcare sector. The stock currently trades at $431.03 with a market capitalization of $32.0B. The stock has gained 66.6% over the past 52 weeks.
Analyst coverage from Oppenheimer provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Humana Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 09, 2026 | Barclays | Overweight | N/A |
| Oct 09, 2026 | Oppenheimer | Outperform | N/A |
| Oct 09, 2026 | Baird | Outperform | N/A |
| Oct 07, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Sep 25, 2026 | Barclays | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View HUM Stock Page
A rating of Outperform from Oppenheimer reflects the analyst's outlook on Humana Inc. (NYSE:HUM). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the HUM forecast page.
Current market data
NYSE · HUM
$417.56
Down: -$2.18 · -0.52%
Live quote updated
Keep reading